Are you searching for the best growth stocks for 2026? The Ranks 21-30 Improvers portfolio offers a unique opportunity for investors aiming to capitalize on undervalued stocks with significant upside potential. Designed as a sector ETF alternative, this portfolio focuses on a score-based strategy to identify companies poised for improvement, targeting growth across diverse industries like healthcare and energy. With only 5 holdings and a solid diversification score of 77.0/100, it balances risk and reward for a focused yet strategic investment approach as we head into Q1 2026.
The stock selection in this portfolio is meticulously curated for the 2026 market outlook. Leading the pack is Alkermes Plc (ALKS), commanding 24.8% of the portfolio in the healthcare sector, a company gaining traction for its innovative biotech solutions and attractive current valuation. Enterprise Products Partners LP (EPD), also at 24.8%, anchors the energy sector with its strong dividend income potential, appealing to investors seeking stability amid energy market shifts. CNX Resources Corp (CNX), comprising the remaining significant holdings, further strengthens the energy focus with its undervalued stock price and growth potential in natural gas exploration. These picks are ideal for those eyeing healthcare stocks and energy investments with long-term value. However, investors should note sector-specific risks, including volatility in energy prices and regulatory changes impacting healthcare stocks.
Tailored for aggressive growth investors and passive income seekers, this portfolio suits those comfortable with medium risk while targeting substantial returns. Whether you’re a beginner investor building a retirement portfolio or a seasoned player hunting for the best tech stocks to buy alongside energy and healthcare exposure, Ranks 21-30 Improvers offers a compelling mix. Stay mindful of market risks like economic downturns or sector downturns as you plan your 2026 investments with this dynamic strategy.